The Oncology Institute, Inc.
NASDAQ:TOIMedical - Care Facilities
-$0.07 today
- Market cap
- $512.91M
- Beta
- 0.41
- P/E (TTM)
- -121.1
- EPS (TTM)
- -$0.04
Volume 1.21M
Average 1.74M
TOI Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
The Oncology Institute, Inc.NASDAQ: TOI
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit grows, but more slowly than its trailing trend
Q1 FY2026 gross profit of $21.7M rose 25.8% year over year, behind the +36.5% change in trailing-twelve-month gross profit. Sequentially, it fell 4.7% from the prior quarter. Over 3 fiscal years it compounded at +13.6% a year.
Context
- Gross profit amounted to 15.2% of revenue in FY2025, up 1.5 pp from a year earlier.
- Gross profit increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +25.8% toward the trailing-twelve-month pace of +36.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 76.44M USD
- Year-over-year change
- +41.6%
- 4-year CAGR
- +17.0%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 76.44M | +41.6% |
| FY2024 | 2024-12-31 | 54M | -9.4% |
| FY2023 | 2023-12-31 | 59.57M | +14.4% |
| FY2022 | 2022-12-31 | 52.09M | +27.5% |
| FY2021 | 2021-12-31 | 40.85M | — |
Gross Profit vs competitors
How TOI compares with its peers on the latest reported figures
- Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +36.5% is the 2nd highest of 10, against a peer median of +1.2%.
- Gross profit amounts to 14.8% of revenue for TOI, versus a peer median of 37.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
AUNAAuna S.A. | LTM Mar 2026 | PEN 1.71B PEN | +1.2% | +23.7% | 37.9% |
| LTM Mar 2026 | $198.84M USD | -22.2% | -32.0% | 19.8% | |
| LTM Mar 2026 | $197.81M USD | +5.8% | +29.0% | 65.5% | |
| LTM Mar 2026 | $177.79M USD | +14.9% | +24.0% | 73.1% | |
| LTM Mar 2026 | $165.27M USD | -2.3% | +14.1% | 79.7% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $83.39M USD | +34.5% | +53.9% | 87.7% |
| LTM Mar 2026 | $80.89M USD | +36.5% | +13.6% | 14.8% | |
| LTM Mar 2026 | -$10.36M USD | +93.0% | — | 11.2% | |
| LTM Mar 2026 | -$123.06M USD | -136.6% | — | 29.9% | |
| LTM Mar 2026 | -$159.48M USD | -716.8% | — | 2.7% | |
| Peer median (excluding TOI) | — | +1.2% | +23.8% | 37.9% | |
Competitors are the stored peer set for TOI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 203M | 252.48M | 324.24M | 393.41M | 502.73M |
| Cost of Revenue | 162.16M | 200.39M | 264.67M | 339.42M | 426.29M |
| Gross Profit | 40.85M | 52.09M | 59.57M | 54M | 76.44M |
| Gross Margin | 20.1% | 20.6% | 18.4% | 13.7% | 15.2% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 105.57M |
| Operating Expenses | 86.71M | 134.04M | 136.59M | 114.12M | 112.52M |
| Depreciation & Amortization | 3.34M | 4.41M | 5.87M | 6.29M | 6.94M |
| EBITDA | (42.04M) | (67.6M) | (54.28M) | (50.88M) | (42.52M) |
| EBITDA Margin | -20.7% | -26.8% | -16.7% | -12.9% | -8.5% |
| Operating Income | (45.86M) | (81.95M) | (77.02M) | (60.12M) | (36.08M) |
| Operating Margin | -22.6% | -32.5% | -23.8% | -15.3% | -7.2% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 320K | 4.08M | 6.78M | 7.5M | 11.28M |
| Other Income / Expenses | 34.26M | 81.86M | (6.09M) | (4.55M) | (24.65M) |
| Income Before Tax | (11.6M) | (91K) | (83.1M) | (64.66M) | (60.74M) |
| Pre-Tax Margin | -5.7% | -0.0% | -25.6% | -16.4% | -12.1% |
| Income Tax Expense | (671K) | (243K) | (36K) | 0 | (131K) |
| Net Income | (10.93M) | 152K | (83.07M) | (64.66M) | (60.61M) |
| Net Margin | -5.4% | 0.1% | -25.6% | -16.4% | -12.1% |
| EPS (Basic) | (0.16) | 0.00 | (0.92) | (0.71) | (0.54) |
| EPS (Diluted) | (0.16) | (0.21) | (0.92) | (0.71) | (0.54) |
| Weighted Avg Shares | 66.23M | 72.79M | 73.75M | 75.04M | 923.89M |
| Weighted Avg Shares (Diluted) | 66.23M | 80.61M | 73.75M | 75.04M | 923.89M |
The Oncology Institute, Inc.
NASDAQ:TOI
Intrinsic Alpha fair value
Locked
Current Price
$5.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.